[The new generation of messenger RNA (mRNA) vaccines against influenza].
La nueva generación de vacunas de ARN mensajero (ARNm) frente a la gripe.
Flu
Vaccine efficacy
messenger RNA vaccines
Journal
Enfermedades infecciosas y microbiologia clinica
ISSN: 1578-1852
Titre abrégé: Enferm Infecc Microbiol Clin
Pays: Spain
ID NLM: 9104081
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
25
05
2021
accepted:
13
07
2021
medline:
7
9
2021
pubmed:
7
9
2021
entrez:
6
9
2021
Statut:
ppublish
Résumé
Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines.
Identifiants
pubmed: 34483424
doi: 10.1016/j.eimc.2021.07.009
pii: S0213-005X(21)00229-9
pmc: PMC8397276
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
spa
Pagination
301-304Informations de copyright
© 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.